- Home
- ANIK vs DRUG Comparison
ANIK vs DRUG Comparison
Compare ANIK & DRUG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ANIK
- DRUG
- Stock Information
- Founded
- ANIK 1983
- DRUG 2019
- Country
- ANIK United States
- DRUG United States
- Employees
- ANIK N/A
- DRUG N/A
- Industry
- ANIK Medical/Dental Instruments
- DRUG Pharmaceuticals and Biotechnology
- Sector
- ANIK Health Care
- DRUG Health Care
- Exchange
- ANIK Nasdaq
- DRUG Nasdaq
- Market Cap
- ANIK 196.6M
- DRUG 233.2M
- IPO Year
- ANIK 1993
- DRUG N/A
- Fundamental
- Price
- ANIK $11.31
- DRUG $27.75
- Analyst Decision
- ANIK Buy
- DRUG Strong Buy
- Analyst Count
- ANIK 1
- DRUG 6
- Target Price
- ANIK $19.00
- DRUG $83.25
- AVG Volume (30 Days)
- ANIK 65.5K
- DRUG 25.9K
- Earning Date
- ANIK 08-07-2025
- DRUG 05-15-2025
- Dividend Yield
- ANIK N/A
- DRUG N/A
- EPS Growth
- ANIK N/A
- DRUG N/A
- EPS
- ANIK N/A
- DRUG N/A
- Revenue
- ANIK $117,053,000.00
- DRUG N/A
- Revenue This Year
- ANIK N/A
- DRUG N/A
- Revenue Next Year
- ANIK $9.70
- DRUG N/A
- P/E Ratio
- ANIK N/A
- DRUG N/A
- Revenue Growth
- ANIK 4.61
- DRUG N/A
- 52 Week Low
- ANIK $10.89
- DRUG $0.93
- 52 Week High
- ANIK $29.12
- DRUG $79.02
- Technical
- Relative Strength Index (RSI)
- ANIK 39.22
- DRUG 41.78
- Support Level
- ANIK $11.17
- DRUG $27.11
- Resistance Level
- ANIK $11.78
- DRUG $28.89
- Average True Range (ATR)
- ANIK 0.36
- DRUG 1.72
- MACD
- ANIK 0.11
- DRUG 0.06
- Stochastic Oscillator
- ANIK 40.78
- DRUG 41.55
About ANIK Anika Therapeutics Inc.
Anika Therapeutics Inc is an orthopedic medicines company. It is committed to improving the lives of patients with degenerative orthopedic diseases and traumatic conditions with clinically meaningful therapies. The company focuses on orthopedics, including osteoarthritis pain management, regenerative solutions, soft tissue repair, and bone preserving joint technologies. Geographically, it derives a majority of its revenue from the United States and also has its presence in Europe and Other countries.
About DRUG Bright Minds Biosciences Inc.
Bright Minds Biosciences Inc is focused on developing novel transformative treatments for neuropsychiatric disorders, epilepsy, and pain. The company has a portfolio of next-generation serotonin agonists designed to target neurocircuit abnormalities that are responsible for difficult to treat disorders such as resistant epilepsy, treatment resistant depression, PTSD, and pain. The company's drugs have been designed to potentially retain the powerful therapeutic aspects of psychedelic and other serotonergic compounds, while minimizing the side effects, thereby creating superior drugs to first-generation compounds, such as psilocybin.